Abstract
The genetics of Alzheimers disease (AD) implies that restoring non-pathological levels or ratios of different amyloid-β (Aβ) peptide species in the brain could prevent the onset or delay the progression of this neurodegenerative disease. In particular, a selective reduction of the longer Aβ(1-42) peptide which is widely believed to be causative of AD is currently seen as an attractive approach for a disease-modifying therapy. Based on the knowledge that Aβ(1-42) and various shorter Aβ peptides are generated by the same γ-secretase enzyme, the concept of allosteric modulation of the cleavage specificity of this aspartic protease has been introduced to the field of protease drug discovery and fuelled novel medicinal chemistry efforts. γ-Secretase modulation holds the promise that chemical entities can be synthesized which restore non-pathological enzyme activity by shifting the actual substrate cleavage towards the generation of shorter Aβ peptides. It can be assumed that this approach has gained considerable attraction for pharmaceutical drug discovery since the development of non-selective protease inhibitors for γ-secretase has been proven to be difficult due to inherent mechanism-based liabilities.
Current Topics in Medicinal Chemistry
Title: γ-Secretase Modulation and its Promise for Alzheimers Disease: a Rationale for Drug Discovery
Volume: 8 Issue: 1
Author(s): Dirk Beher
Affiliation:
Abstract: The genetics of Alzheimers disease (AD) implies that restoring non-pathological levels or ratios of different amyloid-β (Aβ) peptide species in the brain could prevent the onset or delay the progression of this neurodegenerative disease. In particular, a selective reduction of the longer Aβ(1-42) peptide which is widely believed to be causative of AD is currently seen as an attractive approach for a disease-modifying therapy. Based on the knowledge that Aβ(1-42) and various shorter Aβ peptides are generated by the same γ-secretase enzyme, the concept of allosteric modulation of the cleavage specificity of this aspartic protease has been introduced to the field of protease drug discovery and fuelled novel medicinal chemistry efforts. γ-Secretase modulation holds the promise that chemical entities can be synthesized which restore non-pathological enzyme activity by shifting the actual substrate cleavage towards the generation of shorter Aβ peptides. It can be assumed that this approach has gained considerable attraction for pharmaceutical drug discovery since the development of non-selective protease inhibitors for γ-secretase has been proven to be difficult due to inherent mechanism-based liabilities.
Export Options
About this article
Cite this article as:
Beher Dirk, γ-Secretase Modulation and its Promise for Alzheimers Disease: a Rationale for Drug Discovery, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334051
DOI https://dx.doi.org/10.2174/156802608783334051 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Yin and Yang of Inflammation
Current Molecular Medicine BMI1 Regulation of Self-Renewal and Multipotency in Human Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Neurotoxicity Induced by Mephedrone: An up-to-date Review
Current Neuropharmacology Nanoparticles and Immune Cells
Current Pharmaceutical Design From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Expression and Functions of Innate Pattern Recognition Receptors in T and B Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?
Current Neuropharmacology Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Possible Neuroprotective Strategies in ALS
Current Neuropharmacology Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Guanine-Quadruplexes Studied by Fluorescence Techniques
Current Analytical Chemistry Substance Use Portrayal in Oscar-nominated Movies
Current Drug Research Reviews The Intriguing Occurrence of Segmental Arterial Mediolysis: Case Report and Concise Literature Review
Cardiovascular & Hematological Disorders-Drug Targets Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Strict Adherence to Guidelines in Decision Making for Coronary Angiography in Patients Who have Survived a Q Wave Myocardial Infarction; 2-Year Outcome in a Greek Population
Vascular Disease Prevention (Discontinued) Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) On the Origin of Cortical Dopamine: Is it a Co-Transmitter in Noradrenergic Neurons?
Current Neuropharmacology